CN103028029B - Traditional Chinese medicine for treating cardiovascular diseases and preparation method thereof - Google Patents
Traditional Chinese medicine for treating cardiovascular diseases and preparation method thereof Download PDFInfo
- Publication number
- CN103028029B CN103028029B CN201210486277.0A CN201210486277A CN103028029B CN 103028029 B CN103028029 B CN 103028029B CN 201210486277 A CN201210486277 A CN 201210486277A CN 103028029 B CN103028029 B CN 103028029B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- parts
- traditional chinese
- fructus trichosanthis
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims description 11
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract description 8
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 14
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 14
- 235000008434 ginseng Nutrition 0.000 claims abstract description 14
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 37
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- 238000000605 extraction Methods 0.000 claims description 18
- 241000180649 Panax notoginseng Species 0.000 claims description 15
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 15
- 241000208340 Araliaceae Species 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 8
- 230000006837 decompression Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000004064 recycling Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 239000002021 butanolic extract Substances 0.000 claims description 3
- 239000002024 ethyl acetate extract Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 9
- 208000029078 coronary artery disease Diseases 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 5
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 4
- 241000721047 Danaus plexippus Species 0.000 abstract description 4
- 208000002193 Pain Diseases 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract description 2
- 230000007812 deficiency Effects 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 4
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 2
- 241000112528 Ligusticum striatum Species 0.000 abstract 2
- 235000002789 Panax ginseng Nutrition 0.000 abstract 2
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 2
- 229940116229 borneol Drugs 0.000 abstract 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 2
- 241000304531 Allium macrostemon Species 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 230000003014 reinforcing effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 description 9
- 238000005325 percolation Methods 0.000 description 8
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 6
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 6
- 208000026106 cerebrovascular disease Diseases 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 230000002526 effect on cardiovascular system Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229930182490 saponin Natural products 0.000 description 5
- 150000007949 saponins Chemical class 0.000 description 5
- 235000017709 saponins Nutrition 0.000 description 5
- 238000000746 purification Methods 0.000 description 4
- 206010008479 Chest Pain Diseases 0.000 description 3
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 3
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 3
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 3
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 3
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine for treating cardiovascular disease. The traditional Chinese medicine is characterized by comprising the following raw materials in parts by weight: 2-4 parts of ginseng, 2-4 parts of panax pseudoginseng, 1-3 parts of ligusticum wallichii, 1-3 parts of longstamen onion bulb, 1-3 parts of full fructus trichosanthis and 0.005-0.02 part of borneol. Fangzhong ginseng and panax pseudoginseng are taken as the monarch drug and have efficacy of greatly reinforcing vital energy, restoring the pulse and relieving desertion, and dispersing stasis and stopping pain; ligusticum wallichii and full fructus trichosanthis are taken as the ministerial drug, are used for promoting qi and activateing blood, activating yang and eliminating stagnation and widening chest and stopping pain, and are matched with the monarch drug to improve comprehensive effect; and borneol is taken as an assistant to induce resuscitation. The traditional Chinese medicine is refined in all-round combination, reasonable in compatibility of medicines and complementary; and by long-time clinical application, the traditional Chinese medicine has better efficacy to people with coronary heart disease and angor pectoris belonging to qi deficiency and blood stasis, so that the medicine is an effective prescription actually.
Description
Technical field
The invention belongs to a kind of Chinese medicine, specifically Chinese medicine of a kind of Cardiovarscular and preparation method thereof.
Background technology
Cardiovascular and cerebrovascular disease refers to that sclerosis occurs for heart and arteries and the heart ischemia that causes or hemorrhage disease, comprises that coronary heart diseases and angina pectoris, hypertension, arrhythmia, myocardial infarction, cerebral infarction wait indefinitely.China die from every year cardiovascular and cerebrovascular disease the annual total death toll of people You300 Duo Wan，Zhan China 50%, and the people 75% who survives disability in various degree, 4% is heavy residual.In recent years, cardiovascular and cerebrovascular disease sickness rate is the trend rising year by year, and particularly its morbidity and dead age are rejuvenation trend day by day, and how effectively control also just causes people's great attention.
At present, treatment cardiovascular and cerebrovascular disease, generally adopt Western medicine to treat, but curative effect is unsatisfactory, and Long-term taking medicine can bring certain dependency.
Summary of the invention
The object of this invention is to provide Chinese medicine of a kind of Cardiovarscular and preparation method thereof, effect is remarkable.
Technical scheme of the present invention is as follows:
A Chinese medicine for Cardiovarscular, is characterized in that being made by the raw material of following weight portion: Radix Ginseng 2-4, Radix Notoginseng 2-4, Rhizoma Chuanxiong 1-3, Bulbus Allii Macrostemonis 1-3, Fructus Trichosanthis 1-3, Borneolum Syntheticum 0.005-0.02.
The Chinese medicine of described Cardiovarscular, is characterized in that being made by the raw material of following weight portion: Radix Ginseng 3, Radix Notoginseng 3, Rhizoma Chuanxiong 2, Bulbus Allii Macrostemonis 2, Fructus Trichosanthis 3, Borneolum Syntheticum 0.01.
The preparation method of the Chinese medicine of described Cardiovarscular, is characterized in that comprising the following steps:
1. Radix Ginseng, Radix Notoginseng, Bulbus Allii Macrostemonis, Fructus Trichosanthis are ground into coarse powder, use 70% ethanol percolate extraction, collect percolate, decompression recycling ethanol, and n-butanol extraction three times of water liquid, collect butanol solution, and reclaim under reduced pressure n-butyl alcohol is also dry, obtains n-butanol extract (I).
2. get Rhizoma Chuanxiong, be ground into fine powder, add 70% ethanol percolate extraction, collect 70% alcoholic solution, decompression recycling ethanol; Water liquid is extracted with ethyl acetate three times, and reclaim under reduced pressure ethyl acetate obtains ethyl acetate extract (II).
I and II are merged, add Borneolum Syntheticum, mix, obtain.
1, Radix Ginseng, Radix Notoginseng, Fructus Trichosanthis and Bulbus Allii Macrostemonis extract the optimization of purification Drying Technology Parameter
Through experiment, preparation method of the present invention is optimised process, on this technique basis, preparation technology parameter is optimized.Adopt HPLC method, take ginsenoside Rg1, ginsenoside Rb1 and arasaponin R1 content is deliberated index, adopt experiment of single factor, the factor extracting method that impact is extracted, extraction solvent, pulverizing medicinal materials granularity, soak time, percolation speed, percolation terminal etc. are investigated.The extraction process of the 4 taste medicines such as final definite Radix Ginseng is: first by 3 times of amount 70% soak with ethanol, spend the night, use 70% ethanol percolation, flow velocity 10mLkg
-1min
-1, collect 13 times of amount 70% ethanol percolation liquid.Radix Notoginseng total arasaponins (ginsenoside Rg1, ginsenoside Rb1 and the arasaponin R1 sum) rate of transform is greater than 90%.
For reducing paste-forming rate, retain effective ingredient, remove invalid impurity, this product adopts n-butanol extraction to carry out purification to total saponins constituents.Final definite this product purifying process is: with n-butyl alcohol, divide three extractions, and each 2 times of volumes of consumption, the Radix Notoginseng total arasaponins rate of transform is greater than 70%.
This product adopts concentrating under reduced pressure and hypobaric drying method to test, with content of the total saponins in radix notoginseng before and after concentrating and being dried, be changed to investigation index, major influence factors temperature to concentrate drying is investigated, result this product is concentrating under reduced pressure under 80 ℃ of (vacuum 0.08Mpa) conditions in temperature, and in temperature, be drying under reduced pressure under 70 ℃ of (vacuum 0.08Mpa) conditions, before and after experiment, content of the total saponins in radix notoginseng does not have significant change.Final definite this product is concentrated, drying condition is: in temperature, being concentrating under reduced pressure under 80 ℃ of (vacuum 0.08Mpa) conditions, is drying under reduced pressure under 70 ℃ of (vacuum 0.08Mpa) conditions in temperature.
2, Rhizoma Chuanxiong extraction and purification process parameter optimization
Adopt HPLC method, take ligustilide content as deliberated index, adopt experiment of single factor, the factor extracting method that impact is extracted, extraction solvent, pulverizing medicinal materials granularity, soak time, percolation speed, percolation terminal etc. are investigated.The extraction process of final definite Rhizoma Chuanxiong is: first by 3 times of amount 75% soak with ethanol, spend the night, use 75% ethanol percolation, flow velocity 10mLkg
-1min
-1, collect 10 times of amount 70% ethanol percolation liquid.The ligustilide rate of transform is greater than 90%.
This product adopts concentrating under reduced pressure method to test, take concentrate before and after ligustilide changes of contents be to investigate index, concentrated major influence factors temperature is investigated, result this product is concentrating under reduced pressure under 60 ℃ of (vacuum 0.08Mpa) conditions in temperature, and before and after experiment, ligustilide changes of contents is less.The concentrated condition of final definite this product is: in temperature, be concentrating under reduced pressure under 60 ℃ of (vacuum 0.08Mpa) conditions, be concentrated into without alcohol taste.
For reducing paste-forming rate, retain effective ingredient, remove invalid impurity, this product adopts ethyl acetate extraction to carry out purification to total phthalide-type composition.Final definite this product purifying process is: by ethyl acetate, divide three extractions, and each 2 times of volumes of consumption, the ligustilide rate of transform is greater than 70%.
Modern pharmacological research result shows, Radix Ginseng and Radix Notoginseng mainly contain take the saponin component that ginsenoside Rg1, ginsenoside Rb1, ginsenoside Re, arasaponin R1 etc. are representative, this constituents has function of promoting blood circulation to disperse blood clots, cardiovascular is had to good dilating effect, can reduce Peripheral resistance, reduce myocardial oxygen consumption, promote collateral circulation, suppress platelet aggregation, angina pectoris is had to good curative effect.Bibliographical information, after Fructus Trichosanthis Bulbus Allii Macrostemonis water extraction, n-butanol extraction position is its effective site that resists myocardial ischemia, main chemical compositions is also saponin component.Rhizoma Chuanxiong mainly contains take the liposoluble ingredient that the phthalide-type composition that ligustilide is representative and the ferulic acid of take be representative, this two constituents has pharmacodynamics effect widely to cardiovascular system, there is ischemia resisting reperfusion injury, dwindle infarction size, antithrombotic forms, reduce blood viscosity, improve the pharmacological action that blood flow becomes.
In side, Radix Ginseng, Radix Notoginseng are monarch drug, its effect strongly invigorating primordial QI, and multiple arteries and veins is admittedly de-, eliminating stasis to stop pain; Rhizoma Chuanxiong, Bulbus Allii Macrostemonis, Fructus Trichosanthis are ministerial drug, for promoting flow of QI and blood, activating YANG and eliminating stagnation, the chest stuffiness relieving pain relieving, coordinate monarch drug to promote comprehensive effect; Assistant with Borneolum Syntheticum with the refreshment of having one's ideas straightened out.The combination refine of full side, compatibility is reasonable, complements each other, and person's curative effect is better through long-term clinical application and coronary heart diseases and angina pectoris, to belong to Qi deficiency blood stasis type, and reality is good recipe.
The specific embodiment
Treatment cardiovascular diseases's Chinese patent medicine, prescription: Radix Ginseng 3g Radix Notoginseng 3g Rhizoma Chuanxiong 2g Bulbus Allii Macrostemonis 2g Fructus Trichosanthis 3g Borneolum Syntheticum 0.01g(mono-consumption per day 13.01g crude drug)
Preparation method:
1. Radix Ginseng, Radix Notoginseng, Bulbus Allii Macrostemonis, Fructus Trichosanthis are ground into coarse powder, use 70% ethanol percolate extraction, collect percolate, decompression recycling ethanol, and n-butanol extraction three times of water liquid, collect butanol solution, and reclaim under reduced pressure n-butyl alcohol is also dry, obtains n-butanol extract (I).
2. get Rhizoma Chuanxiong, be ground into fine powder, add 70% ethanol percolate extraction, collect 70% alcoholic solution, decompression recycling ethanol; Water liquid is extracted with ethyl acetate three times, and reclaim under reduced pressure ethyl acetate obtains ethyl acetate extract (II).
I and II are merged, add Borneolum Syntheticum, mix, obtain.
Coronary heart disease treatment clinical experiment
Choose patients with coronary heart disease 50 examples, male 28 examples wherein, female's 22 examples, age distribution 42-82 is negative, and diagnostic criteria for coronary heart disease meets WHO " about name and the diagnostic criteria of ischemic heart desease " in 1979.
On former treatment basis, the former medicine of taking of stopping using, takes medicine of the present invention, 10 days courses for the treatment of, continuous two courses for the treatment of.
Curative effect determinate standard:
Effective: chest pain, cardio palmus shape disappear substantially, electrocardiogram demonstration ischemic state recovers normal substantially;
Effective: chest pain, cardio palmus shape alleviate or attack times reduces, electrocardiogram shows that myocardial ischemia improves:
Invalid: chest pain, cardio palmus shape are not improved, electrocardiogram shows that ischemic state does not take a favorable turn as invalid.
Therapeutic outcome:
Effective 29 examples, effective 16 examples, invalid 5 examples, visible, medicine of the present invention has good therapeutical effect to cardiovascular and cerebrovascular disease.And the raw materials used Chinese medicine that is of medicine of the present invention, has no side effect, and can not produce any harm to human body.
Claims (2)
1. a preparation method for the Chinese medicine of Cardiovarscular, is characterized in that being made by the raw material of following weight portion: Radix Ginseng 2-4, Radix Notoginseng 2-4, Rhizoma Chuanxiong 1-3, Bulbus Allii Macrostemonis 1-3, Fructus Trichosanthis 1-3, Borneolum Syntheticum 0.005-0.02; Preparation comprises the following steps:
1. Radix Ginseng, Radix Notoginseng, Bulbus Allii Macrostemonis, Fructus Trichosanthis are ground into coarse powder, use 70% ethanol percolate extraction, collect percolate, decompression recycling ethanol, and n-butanol extraction three times of water liquid, collect butanol solution, and reclaim under reduced pressure n-butyl alcohol is also dry, obtains n-butanol extract (I);
2. get Rhizoma Chuanxiong, be ground into fine powder, add 70% ethanol percolate extraction, collect 70% alcoholic solution, decompression recycling ethanol; Water liquid is extracted with ethyl acetate three times, and reclaim under reduced pressure ethyl acetate obtains ethyl acetate extract (II); I and II are merged, add Borneolum Syntheticum, mix, obtain.
2. according to the preparation method of the Chinese medicine of the Cardiovarscular described in claim 1, it is characterized in that being made by the raw material of following weight portion: Radix Ginseng 3, Radix Notoginseng 3, Rhizoma Chuanxiong 2, Bulbus Allii Macrostemonis 2, Fructus Trichosanthis 3, Borneolum Syntheticum 0.01.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210486277.0A CN103028029B (en) | 2012-11-26 | 2012-11-26 | Traditional Chinese medicine for treating cardiovascular diseases and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210486277.0A CN103028029B (en) | 2012-11-26 | 2012-11-26 | Traditional Chinese medicine for treating cardiovascular diseases and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103028029A CN103028029A (en) | 2013-04-10 |
| CN103028029B true CN103028029B (en) | 2014-03-12 |
Family
ID=48015758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210486277.0A Active CN103028029B (en) | 2012-11-26 | 2012-11-26 | Traditional Chinese medicine for treating cardiovascular diseases and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103028029B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103566146B (en) * | 2013-10-10 | 2015-09-30 | 广西中医药大学 | A kind of medicine for the treatment of cerebral infarction and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101129731A (en) * | 2007-08-28 | 2008-02-27 | 邓世明 | Compound for treating obstruction of qi in chest heart ache and formulated product of the same |
-
2012
- 2012-11-26 CN CN201210486277.0A patent/CN103028029B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101129731A (en) * | 2007-08-28 | 2008-02-27 | 邓世明 | Compound for treating obstruction of qi in chest heart ache and formulated product of the same |
Non-Patent Citations (2)
| Title |
|---|
| 刘芳等.益气活血中药改善冠心病患者血管内皮功能临床研究进展.《中医药临床杂志》.2012,第24卷(第1期),78-80. |
| 益气活血中药改善冠心病患者血管内皮功能临床研究进展;刘芳等;《中医药临床杂志》;20120131;第24卷(第1期);78-80 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103028029A (en) | 2013-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101972395B (en) | Calming and decompressing traditional Chinese medicine composition and preparation method thereof | |
| CN102614387A (en) | Traditional Chinese medicine for prevention and treatment of stroke and preparation method thereof | |
| CN102366508A (en) | Traditional Chinese medicine preparation for treating obstructive infertility of fallopian tube | |
| CN103961559A (en) | Styptic powder with dendrobium officinale | |
| CN101391056B (en) | Medicine for treating aplastic anemia | |
| CN103028029B (en) | Traditional Chinese medicine for treating cardiovascular diseases and preparation method thereof | |
| CN105250427A (en) | Pharmaceutical composition for treating heart diseases | |
| CN103169855A (en) | Drug composition for treating chronic heart failure | |
| CN102488774B (en) | Chinese medicinal powder for treating canker sore and preparation method thereof | |
| CN102488783A (en) | Symptom Chinese patent medicine for blood deficiency | |
| CN102526385B (en) | Medicament for treating climacteric syndrome | |
| CN102266481B (en) | Chinese medicinal preparation for treating chronic cerebral circulation insufficiency | |
| CN105641370B (en) | The Chinese medicine composition for treating perimenopausal syndrome | |
| CN103585366A (en) | Medicine for treating ischemic hyperlipidemia and preparation method thereof | |
| CN103520315A (en) | Medicinal composition for treating gynecological vaginitis and preparation method of medicinal composition | |
| CN103251786B (en) | Medicament for treating hyperlipaemia and preparation method thereof | |
| CN102366453A (en) | Traditional Chinese medicinal preparation for treating strokes and Bi syndromes | |
| CN103182058A (en) | Medicine for treating chronic pelvic inflammatory disease and preparation method thereof | |
| CN116870129B (en) | Compound traditional Chinese medicine for warming channel and dredging collaterals for treating reynolds phenomenon related to connective tissue diseases | |
| CN101647920B (en) | Medicament for treating scar and preparation method thereof | |
| CN110812451B (en) | Pain arthralgia pill and preparation method and application thereof | |
| CN101607007B (en) | Traditional Chinese medicine preparation for treating cerebral circulation insufficiency | |
| CN101904911A (en) | External application drug for treating eczema and preparation method thereof | |
| CN101112494B (en) | Medicine for treating coronary disease and method for preparing the same | |
| CN105395793A (en) | Application of traditional Chinese medicine composition to preparing medicine treating chronic stable angina pectoris |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 236800 No. 23, Lixin Road, Qiaocheng District, Anhui, Bozhou Patentee after: HUATUO CHINESE MEDICINES CO.,LTD. Address before: 236800 No. 23, Lixin Road, Qiaocheng District, Anhui, Bozhou Patentee before: ANHUI HUATUO TRADITIONAL CHINESE MEDICINE Co.,Ltd. |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Traditional Chinese medicine for treating cardiovascular diseases and preparation method thereof Effective date of registration: 20161206 Granted publication date: 20140312 Pledgee: Agricultural Bank China Limited by Share Ltd. Bozhou Qiaocheng branch Pledgor: HUATUO CHINESE MEDICINES CO.,LTD. Registration number: 2016990001068 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180807 Granted publication date: 20140312 Pledgee: Agricultural Bank China Limited by Share Ltd. Bozhou Qiaocheng branch Pledgor: HUATUO CHINESE MEDICINES CO.,LTD. Registration number: 2016990001068 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The invention relates to a traditional Chinese medicine for treating cardiovascular diseases and a preparation method thereof Effective date of registration: 20211230 Granted publication date: 20140312 Pledgee: Bozhou Jingzhong Private Enterprise Financing Guarantee Co.,Ltd. Pledgor: HUATUO CHINESE MEDICINES CO.,LTD. Registration number: Y2021980017023 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220914 Granted publication date: 20140312 Pledgee: Bozhou Jingzhong Private Enterprise Financing Guarantee Co.,Ltd. Pledgor: HUATUO CHINESE MEDICINES CO.,LTD. Registration number: Y2021980017023 |